Correction to: PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome (Nature Structural & Molecular Biology, (2015), 22, 5, (362-369), 10.1038/nsmb.3014);PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome

Nature Structural and Molecular Biology

Volumn 22, Issue 5, 2015, Pages 362-369

  Kroeze, Wesley K ^a,b   Sassano, Maria F ^a,b   Huang, Xi Ping ^a,b   Lansu, Katherine ^a   McCorvy, John D ^a   Giguère, Patrick M ^a   Sciaky, Noah ^a   Roth, Bryan L ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,4,4A,5,12,12AALPHA OCTAHYDRO 4AALPHA (3 HYDROXYPHENYL) 2 METHYLQUINOLINO[2,3 G]ISOQUINOLINE; 2 [5 (2,6 DIMETHOXYPHENYL) 1 [4 [N (3 DIMETHYLAMINOPROPYL) N METHYLCARBAMOYL] 2 ISOPROPYLPHENYL] 1H PYRAZOL 3 YLCARBONYLAMINO]ADAMANTANE 2 CARBOXYLIC ACID; BESTATIN; BETA ARRESTIN; CLOZAPINE; DEXTROMETHORPHAN; DOPAMINE; FLUOXETINE; G PROTEIN COUPLED RECEPTOR; ISOPRENALINE; KETOTIFEN; LEVOCABASTINE; LYSERGIDE; MECLINERTANT; NATEGLINIDE; NORADRENALIN; OPIATE AGONIST; PIZOTIFEN; QUINPIROLE; SALVINORIN A; SAQUINAVIR; LIGAND; RETINA S ANTIGEN; SMALL INTERFERING RNA;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG TARGETING; EC50; GENE EXPRESSION; HEK293 CELL LINE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN GENOME; LIGAND BINDING; PRESTO TANGO ASSAY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; VALIDATION STUDY; AGONISTS; AMINO ACID SEQUENCE; ANTAGONISTS AND INHIBITORS; BIOASSAY; GENETIC TRANSCRIPTION; METABOLISM; PROCEDURES; RNA INTERFERENCE;

AMINO ACID SEQUENCE; ARRESTINS; BIOLOGICAL ASSAY; HUMANS; LIGANDS; RECEPTORS, G-PROTEIN-COUPLED; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION;

EID: 84929285245     PISSN: 15459993     EISSN: 15459985     Source Type: Journal    
DOI: 10.1038/s41594-023-01129-x     Document Type: Erratum

References (50)

1. Allen, J.A. & Roth, B.L. Strategies to discover unexpected targets for drugs active at G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 51, 117-144 (2011).
2. Bjarnadóttir, T.K. et al. Comprehensive repertoire and phylogenetic analysis of the G protein-coupled receptors in human and mouse. Genomics 88, 263-273 (2006).
3. Fredriksson, R. & Schioth, H.B. The repertoire of G-protein-coupled receptors in fully sequenced genomes. Mol. Pharmacol. 67, 1414-1425 (2005).
4. Vassilatis, D.K. et al. The G protein-coupled receptor repertoires of human and mouse. Proc. Natl. Acad. Sci. USA 100, 4903-4908 (2003).
5. Hopkins, A.L. & Groom, C.R. The druggable genome. Nat. Rev. Drug Discov. 1, 727-730 (2002).
6. Rask-Andersen, M., Masuram, S. & Schioth, H.B. The druggable genome: evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication. Annu. Rev. Pharmacol. Toxicol. 54, 9-26 (2014).
7. Edwards, A.M. et al. Too many roads not taken. Nature 470, 163-165 (2011).
8. i-coupled receptors. Anal. Biochem. 270, 242-248 (1999).
9. Eglen, R.M., Bosse, R. & Reisine, T. Emerging concepts of guanine nucleotide-binding protein-coupled receptor (GPCR) function and implications for high throughput screening. Assay Drug Dev. Technol. 5, 425-451 (2007).
10. Emkey, R. & Rankl, N.B. Screening G protein-coupled receptors: measurement of intracellular calcium using the fluorometric imaging plate reader. Methods Mol. Biol. 565, 145-158 (2009).
11. Hill, S.J., Williams, C. & May, L.T. Insights into GPCR pharmacology from the measurement of changes in intracellular cyclic AMP; advantages and pitfalls of differing methodologies. Br. J. Pharmacol. 161, 1266-1275 (2010).
12. Liu, B. & Wu, D. Analysis of the coupling of G12/13 to G protein-coupled receptors using a luciferase reporter assay. Methods Mol. Biol. 237, 145-149 (2004).
13. Rodrigues, D.J. & McLoughlin, D. Using reporter gene technologies to detect changes in cAMP as a result of GPCR activation. Methods Mol. Biol. 552, 319-328 (2009).
14. Siehler, S. & Guerini, D. Novel GPCR screening approach: indirect identification of S1P receptor agonists in antagonist screening using a calcium assay. J. Recept. Signal Transduct. Res. 26, 549-575 (2006).
15. Lefkowitz, R.J. & Shenoy, S.K. Transduction of receptor signals by beta-arrestins. Science 308, 512-517 (2005).
16. Roth, B.L. & Marshall, F.H. NOBEL 2012 Chemistry: studies of a ubiquitous receptor family. Nature 492, 57 (2012).
17. Barak, L.S., Ferguson, S.S., Zhang, J. & Caron, M.G. A beta-arrestin/green fluorescent protein biosensor for detecting G protein-coupled receptor activation. J. Biol. Chem. 272, 27497-27500 (1997).
18. Angers, S. et al. Detection of beta 2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET). Proc. Natl. Acad. Sci. USA 97, 3684-3689 (2000).
19. Yan, Y.X. et al. Cell-based high-throughput screening assay system for monitoring G protein-coupled receptor activation using beta-galactosidase enzyme complementation technology. J. Biomol. Screen. 7, 451-459 (2002).
20. Barnea, G. et al. The genetic design of signaling cascades to record receptor activation. Proc. Natl. Acad. Sci. USA 105, 64-69 (2008).
21. Fang, Y., Li, G. & Ferrie, A.M. Non-invasive optical biosensor for assaying endogenous G protein-coupled receptors in adherent cells. J. Pharmacol. Toxicol. Methods 55, 314-322 (2007).
22. Hennen, S. et al. Decoding signaling and function of the orphan G protein-coupled receptor GPR17 with a small-molecule agonist. Sci. Signal. 6, ra93 (2013).
23. Guan, X.M., Kobilka, T.S. & Kobilka, B.K. Enhancement of membrane insertion and function in a type IIIb membrane protein following introduction of a cleavable signal peptide. J. Biol. Chem. 267, 21995-21998 (1992).
24. Hanson, B.J. et al. A homogeneous fluorescent live-cell assay for measuring 7-transmembrane receptor activity and agonist functional selectivity through beta-arrestin recruitment. J. Biomol. Screen. 14, 798-810 (2009).
25. Kim, K.M. & Caron, M.G. Complementary roles of the DRY motif and C-terminus tail of GPCRS for G protein coupling and beta-arrestin interaction. Biochem. Biophys. Res. Commun. 366, 42-47 (2008).
26. Vrecl, M. et al. Beta-arrestin-based Bret2 screening assay for the "non"-beta-arrestin binding CB1 receptor. J. Biomol. Screen. 14, 371-380 (2009).
27. Cho, D.I., Beom, S., Van Tol, H.H., Caron, M.G. & Kim, K.M. Characterization of the desensitization properties of five dopamine receptor subtypes and alternatively spliced variants of dopamine D2 and D4 receptors. Biochem. Biophys. Res. Commun. 350, 634-640 (2006).
28. Jensen, D.D. et al. The bile acid receptor TGR5 does not interact with beta-arrestins or traffic to endosomes but transmits sustained signals from plasma membrane rafts. J. Biol. Chem. 288, 22942-22960 (2013).
29. Goupil, E. et al. Biasing the prostaglandin F2α receptor responses toward EGFR-dependent transactivation of MAPK. Mol. Endocrinol. 26, 1189-1202 (2012).
30. Tulipano, G. et al. Differential beta-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes. J. Biol. Chem. 279, 21374-21382 (2004).
31. Richard, F., Barroso, S., Martinez, J., Labbe-Jullie, C. & Kitabgi, P. Agonism, inverse agonism, and neutral antagonism at the constitutively active human neurotensin receptor 2. Mol. Pharmacol. 60, 1392-1398 (2001).
32. Vita, N. et al. Neurotensin is an antagonist of the human neurotensin NT2 receptor expressed in Chinese hamster ovary cells. Eur. J. Pharmacol. 360, 265-272 (1998).
33. Keiser, M.J. et al. Predicting new molecular targets for known drugs. Nature 462, 175-181 (2009).
34. Auld, D.S. et al. Characterization of chemical libraries for luciferase inhibitory activity. J. Med. Chem. 51, 2372-2386 (2008).
35. Auld, D.S., Thorne, N., Maguire, W.F. & Inglese, J. Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression. Proc. Natl. Acad. Sci. USA 106, 3585-3590 (2009).
36. Auld, D.S., Thorne, N., Nguyen, D.T. & Inglese, J. A specific mechanism for nonspecific activation in reporter-gene assays. ACS Chem. Biol. 3, 463-470 (2008).
37. Southern, C. et al. Screening beta-arrestin recruitment for the identification of natural ligands for orphan G-protein-coupled receptors. J. Biomol. Screen. 18, 599-609 (2013).
38. Allen, J.A. et al. Discovery of beta-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc. Natl. Acad. Sci. USA 108, 18488-18493 (2011).
39. Fenalti, G. et al. Molecular control of δ-opioid receptor signalling. Nature 506, 191-196 (2014).
40. White, K.L. et al. Identification of novel functionally selective kappa-opioid receptor scaffolds. Mol. Pharmacol. 85, 83-90 (2014).
41. Wu, H. et al. Structure of the human κ-opioid receptor in complex with JDTic. Nature 485, 327-332 (2012).
42. Wacker, D. et al. Structural features for functional selectivity at serotonin receptors. Science 340, 615-619 (2013).
43. Stanasila, L., Abuin, L., Dey, J. & Cotecchia, S. Different internalization properties of the alpha1a- and alpha1b-adrenergic receptor subtypes: the potential role of receptor interaction with beta-arrestins and AP50. Mol. Pharmacol. 74, 562-573 (2008).
44. Turu, G. et al. Differential beta-arrestin binding of AT1 and AT2 angiotensin receptors. FEBS Lett. 580, 41-45 (2006).
45. Cao, W. et al. Direct binding of activated c-Src to the beta 3-adrenergic receptor is required for MAP kinase activation. J. Biol. Chem. 275, 38131-38134 (2000).
46. Solinski, H.J., Gudermann, T. & Breit, A. Pharmacology and signaling of MAS-related G protein-coupled receptors. Pharmacol. Rev. 66, 570-597 (2014).
47. Liu, Q. et al. Sensory neuron-specific GPCR Mrgprs are itch receptors mediating chloroquine-induced pruritus. Cell 139, 1353-1365 (2009).
48. Twaites, B., Wilton, L.V., Layton, D. & Shakir, S.A. Safety of nateglinide as used in general practice in England: results of a prescription-event monitoring study. Acta Diabetol. 44, 233-239 (2007).
49. Katritch, V., Cherezov, V. & Stevens, R.C. Diversity and modularity of G protein-coupled receptor structures. Trends Pharmacol. Sci. 33, 17-27 (2012).
50. Jordan, M., Schallhorn, A. & Wurm, F.M. Transfecting mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitate formation. Nucleic Acids Res. 24, 596-601 (1996).